Melbourne, Australia, November 2018: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases is pleased to announce the appointments of five members to its Scientific and Clinical Advisory Board.
The new advisory board will support Certa as it prepares to advance its novel precision medicines for fibrotic diseases through clinical development.
Certa Therapeutics is currently progressing its clinical development program for a novel therapeutic platform of precision medicines for the treatment of serious inflammatory and fibrotic diseases including systemic sclerosis (SSc) and chronic kidney disease (CKD). Certa is using genetic analysis to identify the most suitable patients for treatment.
The board comprises global experts in nephrology and fibrotic diseases and is chaired by Dr Paolo Martini who has extensive experience in discovery research- and molecular biology in fibrosis and rare diseases.
World experts in nephrology joining the board include Prof Matthias Kretzler (US), Prof Adeera Levin (Canada) and Prof Kai-Uwe Eckardt (Germany).
Professor Darren Kelly, Founder and CEO of Certa has also joined the board and brings extensive experience in the field of translational research and novel interventions, many of which have had a direct impact on human disease.
“We are extremely pleased to have this distinguished panel of researchers join Certa Therapeutics Scientific and Clinical Advisory Board. Each of the board member’s expertise will be of great benefit for us as we progress through clinical development,” said Prof. Kelly.